**Chapter 9**

*DNA - Damages and Repair Mechanisms*

Inhibitor Resistance. Cancer Res. 2019;79:2812-2820. DOI:10.1158/0008-

[121] Yang S, Wei J, Cui YH, et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10:2782. DOI:10.1038/

epitranscriptome m6A reader YTHDF1 expression in colorectal cancer. Oncotarget. 2017;9:7476-7486. DOI:10.18632/oncotarget.23554

5472.CAN-18-3592

s41467-019-10669-0

ja3064149

[122] Chen, B.; Ye, F.; Yu, L.; Jia, G.; Huang, X.; Zhang, X.; Peng, S.; Chen, K.;Wang, M.; Gong, S.; et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J. Am. Chem. Soc. 2012, 134, 17963-17971. DOI:10.1021/

[123] Zhou Y, Yin Z, Hou B, et al. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets. Cancer Manag Res. 2019;11:3921-3931.

DOI:10.2147/CMAR.S191565

through YTHDF2-dependent

DOI:10.1002/hep.29683

embj.2019103181

Hepatology. 2018;67:2254-2270.

[124] Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferaselike 3 promotes liver cancer progression

posttranscriptional silencing of SOCS2.

[125] Lin Z, Niu Y, Wan A, et al. RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39:e103181. DOI:10.15252/

[126] Taketo K, Konno M, Asai A, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52:621-629.

[127] Nishizawa Y, Konno M, Asai A, et al. Oncogene c-Myc promotes

DOI:10.3892/ijo.2017.4219

**188**
